Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver

M Del Ben, L Polimeni, F Baratta, S Bartimoccia, R Carnevale, L Loffredo, P Pignatelli, F Violi, F Angelico, M Del Ben, L Polimeni, F Baratta, S Bartimoccia, R Carnevale, L Loffredo, P Pignatelli, F Violi, F Angelico

Abstract

Background & Aims. Hepatocyte apoptosis may play a role in progression of nonalcoholic fatty liver and oxidative stress seems one of the key mechanisms responsible for liver damage. The aim was to determine the association of oxidative stress with cytokeratin-18 M30 fragment levels, a marker of hepatocyte apoptosis. Methods. Steatosis severity was defined according to Hamaguchi's echographic criteria in 209 patients with nonalcoholic fatty liver. Serum cytokeratin-18, urinary 8-iso-prostaglandin F2 α , soluble NOX2-derived peptide, and adiponectin were measured. Results. Serum cytokeratin-18 progressively increased with steatosis severity (from 169.5 (129.3/183.8) to 176 (140/190) and 180 (169.5/192.5) μ IU/mL in mild, moderate, and severe steatosis, respectively; P < 0.01). After stratification by cytokeratin-18 tertiles, a significant progression of body mass index, HOMA-IR, triglycerides, urinary 8-iso-PGF2 α , soluble NOX2-derived peptide, and of the prevalence of diabetes and severe steatosis was found, while HDL-cholesterol and adiponectin progressively decreased. A positive correlation between cytokeratin-18 and body mass index, HOMA-IR, Hamaguchi's score, urinary 8-iso-PGF2 α , and soluble NOX2-derived peptide and a negative correlation between cytokeratin-18 and HDL-cholesterol and adiponectin were found. Body mass index, adiponectin, and soluble NOX2-derived peptide were independent predictors of serum cytokeratin-18 levels (adjusted R (2) = 0.36). Conclusion. We support an association between oxidative stress and severity of liver damage in patients with nonalcoholic fatty liver.

References

    1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–1395.
    1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology and Therapeutics. 2011;34(3):274–285.
    1. Leite NC, Salles GF, Araujo ALE, Villela-Nogueira CA, Cardoso CRL. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver International. 2009;29(1):113–119.
    1. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Annals of Internal Medicine. 2000;132(2):112–117.
    1. Angulo P. Medical progress: nonalcoholic fatty liver disease. The New England Journal of Medicine. 2002;346(16):1221–1231.
    1. Day CP. Pathogenesis of steatohepatitis. Bailliere’s Best Practice and Research in Clinical Gastroenterology. 2002;16(5):663–678.
    1. Feldstein AE, Wieckowska A, Lopez AR, Liu Y-C, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072–1078.
    1. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004;39(2):273–278.
    1. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125(2):437–443.
    1. Report of A WHO ConsultAtion. Geneva, Switzerland: World Health Organisation; 1999. World Health Organisation Definition diagnosis and classification of diabetes mellitus and its complications.
    1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–2752.
    1. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854.
    1. Saverymuttu SH, Joseph AEA, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. British Medical Journal. 1986;292(6512):13–15.
    1. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. The American Journal of Gastroenterology. 2007;102(12):2708–2715.
    1. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.
    1. Pignatelli P, Carnevale R, Cangemi R, et al. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30(2):360–367.
    1. Wang Z, Ciabattoni G, Creminon C, et al. Immunological characterization of urinary 8-epi-prostaglandin F(2α) excretion in man. Journal of Pharmacology and Experimental Therapeutics. 1995;275(1):94–100.
    1. Il'yasova D, Scarbrough P, Spasojevic I. Urinary biomarkers of oxidative status. Clinica Chimica Acta. 2012;413:1446–1453.
    1. Montuschi P, Barnes PJ, Roberts LJ., II Isoprostanes: markers and mediators of oxidative stress. The FASEB Journal. 2004;18(15):1791–1800.
    1. Praticò D. Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis. 2008;201(1):8–16.
    1. Cave AC, Brewer AC, Narayanapanicker A, et al. NADPH oxidases in cardiovascular health and disease. Antioxidants and Redox Signaling. 2006;8(5-6):691–728.
    1. Cangemi R, Angelico F, Loffredo L, et al. Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: effect of ascorbic acid. Free Radical Biology and Medicine. 2007;43(5):853–859.
    1. Angelico F, Loffredo L, Pignatelli P, et al. Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Internal and Emergency Medicine. 2012;7:219–227.
    1. Loffredo L, Martino F, Carnevale R, et al. Obesity and hypercholesterolemia are associated with NOX-2 generated oxidative stress and arterial dysfunction. Journal of Pediatrics. 2012;161:1004–1009.
    1. Del Ben M, Fabiani M, Loffredo L, et al. Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment. BMC Pulmonary Medicine. 2012;12, article 36
    1. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27–33.
    1. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854.
    1. Treeprasertsuk S, Björnsson E, Enders F, et al. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World Journal of Gastroenterology. 2013;19:1219–1229.
    1. Carnevale R, Pignatelli P, di Santo S, et al. Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. Atherosclerosis. 2010;213(1):225–234.
    1. Gustafsson S, Lind L, Söderberg S, et al. Oxidative stress and inflammatory markers in relation to circulating levels of adiponectin. Obesity. 2013;21(7):1467–1473.
    1. Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M, Kohno N. A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metabolism. 2005;54(2):194–199.
    1. Arvaniti VA, Thomopoulos KC, Tsamandas A, et al. Serum adiponectin levels in different types of non alcoholic liver disease: correlation with steatosis, necroinflammation and fibrosis. Acta Gastro-Enterologica Belgica. 2008;71(4):355–360.
    1. Lemoine M, Ratziu V, Kim M, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver International. 2009;29(9):1431–1438.
    1. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60(3):313–326.
    1. Palmentieri B, de Sio I, la Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Digestive and Liver Disease. 2006;38(7):485–489.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться